RENBP Inhibitors
RENBP inhibitors encompass a variety of chemical agents that target different components of the renin-angiotensin-aldosterone system (RAAS), ultimately leading to the inhibition of RENBP activity. Direct inhibition occurs through compounds that bind to the active site of renin, thereby preventing its interaction with substrates and subsequent catalytic activity, which is essential for the conversion of angiotensinogen to angiotensin I. This inhibition effectively reduces the need for RENBP's role in stabilizing renin and facilitating its activity. Other inhibitors work by diminishing the production or action of angiotensin II, the primary effector of the RAAS. This is achieved by blocking the angiotensin-converting enzyme or the angiotensin II receptors, which leads to the reduced expression and function of RENBP due to the decreased substrate availability and lesser demand for renin's conversion action.
Indirect pathways of inhibition also play a significant role, where compounds influence the RAAS upstream or downstream of RENBP's direct involvement. These can include molecules that alter the balance of electrolytes, such as sodium and potassium, which are critical regulators of RAAS activity and, by extension, influence RENBP function. By modulating the concentrations of these ions, the inhibitors can affect the signaling pathways that control processes in which the RAAS is intimately involved. Furthermore, some agents may target the synthesis of aldosterone, a hormone regulated by angiotensin II and renin, which in turn can alter RENBP expression and activity as part of a feedback mechanism.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Losartan | 114798-26-4 | sc-353662 | 100 mg | $130.00 | 18 | |
Angiotensin II receptor type 1 (AT1) antagonist that leads to aldosterone release, which in turn can decrease the necessity for RENBP's role in renin activity as part of the renin-angiotensin-aldosterone system. | ||||||
Eprosartan | 133040-01-4 | sc-207631 | 10 mg | $169.00 | 1 | |
AT1 antagonist that blocks the actions of angiotensin II, thereby diminishing the signaling pathway that RENBP is involved in, ultimately leading to a decrease in renin's catalytic activity. | ||||||
Candesartan | 139481-59-7 | sc-217825 sc-217825B sc-217825A | 10 mg 100 mg 1 g | $47.00 $94.00 $151.00 | 6 | |
AT1 antagonist that inhibits the binding of angiotensin II to AT1 receptors, reducing the effects of angiotensin II and consequently the interaction of renin with RENBP, indirectly inhibiting RENBP's function. | ||||||
Valsartan | 137862-53-4 | sc-220362 sc-220362A sc-220362B | 10 mg 100 mg 1 g | $40.00 $92.00 $122.00 | 4 | |
AT1 receptor blocker that prevents angiotensin II from exerting its effects, which would diminish the need for RENBP's renin-binding activity as part of the renin-angiotensin system regulation. | ||||||
Telmisartan | 144701-48-4 | sc-204907 sc-204907A | 50 mg 100 mg | $72.00 $94.00 | 8 | |
AT1 antagonist that not only blocks the effects of angiotensin II but also partially activates peroxisome proliferator-activated receptor gamma (PPARγ), potentially altering the renin-angiotensin system and, hence, the need for RENBP functionality. | ||||||
Irbesartan | 138402-11-6 | sc-218603 sc-218603A | 10 mg 50 mg | $106.00 $303.00 | 3 | |
AT1 blocker that inhibits angiotensin II-induced effects, effectively reducing the activity within the renin-angiotensin-aldosterone system and consequently the role of RENBP in modulating renin activity. | ||||||
Furosemide | 54-31-9 | sc-203961 | 50 mg | $41.00 | ||
Inhibits the Na+/K+/2Cl- co-transporter, which can indirectly decrease renin levels and, therefore, RENBP's interaction with renin. | ||||||
Spironolactone | 52-01-7 | sc-204294 | 50 mg | $109.00 | 3 | |
Aldosterone antagonist that can lead to a decrease in the compensatory secretion of renin and thus the requirement for RENBP's renin-binding capability. | ||||||
Hydrochlorothiazide | 58-93-5 | sc-207738 sc-207738A sc-207738B sc-207738C sc-207738D | 5 g 25 g 50 g 100 g 250 g | $55.00 $240.00 $333.00 $562.00 $988.00 | ||
Thiazide that indirectly reduces the need for renin activity and, consequently, the functional importance of RENBP. | ||||||
Chlorthalidone | 77-36-1 | sc-207427 | 25 mg | $243.00 | 1 | |
Thiazide-like compound that can lead to a decrease in plasma renin activity and a reduced interaction with RENBP. | ||||||